Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFatigue is a recognised side effect of semaglutide, reported by a meaningful proportion of participants in clinical trials. It tends to be most noticeable in the first few weeks of treatment or after a dose increase, and for most people it settles as the body adjusts. That said, sleepiness and tiredness vary considerably between individuals, and a GPhC-registered prescriber needs to assess the full picture before any changes are made. These are prescription-only medicines, and suitability is always a clinical decision. The NHS semaglutide information page lists fatigue among the side effects to be aware of.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 study, published in the New England Journal of Medicine, is the landmark phase 3 trial for semaglutide 2.4mg in weight management. It randomised 1,961 adults with obesity over 68 weeks and tracked adverse events systematically. Fatigue was among the side effects reported more frequently in the semaglutide group than in the placebo group, alongside the more widely discussed gastrointestinal symptoms. The trial's authors classified most instances as mild to moderate in severity. That context matters: it confirms the tiredness is real and documented, not imagined, but it also puts it in proportion. The majority of participants completed the trial, suggesting that fatigue, where it occurred, was manageable rather than treatment-limiting for most people. If you want to read the published data directly, the STEP 1 paper on the NEJM website is freely accessible. The pattern seen in STEP 1 is consistent with what clinicians observe in practice: a burst of tiredness early on, which tends to resolve once the body has adapted to the new dose level.
Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, increases feelings of fullness, and reduces appetite, which is why it works for weight management. Those same mechanisms can, indirectly, contribute to tiredness. When appetite falls sharply, some people eat significantly less than their body is used to, which can mean less fuel available day-to-day, particularly in the first weeks. Protein intake sometimes drops alongside overall calories, and that can compound the low-energy feeling. There is also a direct central effect: GLP-1 receptors are present in the brain, and changes in the gut-brain signalling pathway may themselves influence energy levels. Separately, the GI side effects (nausea, disturbed digestion) can disrupt sleep quality, so tiredness the next day may be downstream of a restless night rather than a direct effect on alertness. For anyone thinking through how semaglutide affects sleep more broadly, these indirect routes are part of the explanation.
Mild tiredness in the first two to four weeks, or for a few days after stepping up to a new dose, is within the expected range. It is worth telling your team about but rarely a reason to pause treatment on its own. Tiredness that is severe, that arrives suddenly outside of a dose change, or that comes with other symptoms (persistent dizziness, unusual thirst, palpitations, low mood) is a different matter. Those combinations can point to something that needs proper assessment rather than watchful waiting. The same applies if you notice that fatigue is worsening over time rather than settling. A quick note here on timing: if your delivery arrives over a bank holiday or at the start of a busy week, do not adjust your injection day without speaking to your prescriber first. Timing changes can affect your experience of side effects, including fatigue. If you are wondering how other people navigate the day-to-day reality of tiredness, the practical page on managing sleepiness with Wegovy covers that ground in more detail. And for a broader look at what Wegovy involves, the Wegovy overview at nume is a useful starting point.
There is good evidence that protein intake and light physical activity both help sustain energy during periods of significant calorie reduction. Eating less does not have to mean eating emptily. A prescriber or dietitian can help you think through what adequate protein and hydration look like on a reduced appetite. Sleep hygiene matters too: if nausea is disturbing your nights, taking your injection at a time of day when side effects are less disruptive (for some people that is the evening) can make a difference, but that is a conversation to have with your clinical team rather than a change to make unilaterally. Caffeine can paper over daytime tiredness but is not a solution if poor sleep is the underlying issue. If you are exploring semaglutide treatment options in the UK or want to understand cost alongside everything else that comes with private treatment, our guide to Wegovy costs in the UK explains what a legitimate price should include. If you have questions about a specific formulation, our guide to Rohm semaglutide covers what you need to know before making any decisions. When you are ready to take the next step, our prescribers are available seven days a week, speak to our prescribers through a free consultation and get a same-day clinical review.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.